(SVA)

Sinovac Biotech Ltd.

Close Price:
1.67

Change:
-0.09 Stock Price Decrease0.09

% Change:
-0.0511363636363636363636363636 Stock Price Decrease5.11 %

Date:
5/18/2012

52 Week:
1.64 - 4.11

Prev Close:
1.76

Open:
1.73

Volume:
88,242

90D Avg. Volume:
108,945

5/18/2012 Range:
1.66 - 1.74

Market Cap:
91,465,900

Trailing PE Ratio:
-23.86

Shares Out:
54,770,000

EPS:
-0.07

Yield:
0.00

Dividend:
0.00

Dividend Date:
-

Quarter End:
6/30/2012

Sinovac Biotech Ltd.

Sector: Healthcare

Industry: Biotechnology

Website: www.sinovac.com

Business Summary: Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. It offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination of hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the influenza A H1N1 virus. The company's pipeline vaccine candidates include a split viron vaccine, which completed Phase II clinical trials for the H5N1 influenza virus; and a SARS vaccine, which completed Phase I clinical trials for the SARS virus. In addition, its pipeline vaccine candidates that completed the pre-clinical trials comprise human vaccines for EV71, pneumococcal conjugate, haemophilus influenzae type b, meningitis, Japanese encephalitis, chickenpox, mumps, and rubella diseases, as well as rabies vaccine for humans and animals. The company markets and sells its vaccine products directly to the provincial and municipal disease control and prevention centers. It has a patent license agreement with the National Institutes of Health; distribution agreements with LG Life Sciences, Ltd. and Glovax C.V.; and a pandemic influenza vaccine co-development agreement with the China Center for Disease Control and Prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.


39 Shangdi Xi Road
Haidian District
Beijing, 100085 China China
P: 86 10 8289 0088
F: 86 10 6296 6910

SVA Earnings Calendar

Q1:
Jan
1
 -
Mar
31
Q2:
Apr
1
 -
Jun
30
Q3:
Jul
1
 -
Sep
30
Q4:
Oct
1
 -
Dec
31
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
12/31/2009
 
 
 
$75,018
$7,313
$25,915
$9,599
$0
$118,312
$0
$24,949
$0
$695
$0
$0
$520
$144,476
 
 
$25,596
$17,698
$6,718
$50,012
$408
$0
$9,589
$13,808
$0
$73,818
 
$0
$0
$0
$43
$0
$0
$42,534
$14,088
$70,658
$69,963
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
128.1%
0.0%
23.3%
29.2%
0.0%
90.0%
0.0%
29.5%
0.0%
(36.2%)
0.0%
0.0%
(8.8%)
73.6%
 
 
112.0%
120.6%
467.9%
135.0%
(81.4%)
0.0%
238.0%
92.2%
0.0%
120.4%
 
0.0%
0.0%
(100.0%)
0.0%
0.0%
0.0%
2.2%
45.3%
42.1%
43.9%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
12/31/2008
 
 
 
$32,894
$0
$21,024
$7,429
$0
$62,281
$0
$19,262
$0
$1,090
$0
$0
$570
$83,203
 
 
$12,072
$8,024
$1,183
$21,279
$2,188
$0
$2,837
$7,185
$0
$33,489
 
$0
$0
$43
$0
$0
$0
$41,630
$9,693
$49,714
$48,623
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
92.7%
0.0%
19.7%
98.3%
0.0%
58.9%
0.0%
21.3%
0.0%
(21.8%)
0.0%
(100.0%)
(17.7%)
44.8%
 
 
(4.0%)
17.4%
14.0%
4.1%
60.1%
0.0%
3.8%
147.9%
0.0%
22.0%
 
0.0%
0.0%
0.0%
(100.0%)
0.0%
0.0%
29.6%
95.2%
65.7%
70.0%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
12/31/2009
$19,958
 
$2,239
$1,095
($5,020)
$24,600
($5,385)
$469
$48,412
 
($4,320)
($7,373)
($64)
($11,693)
 
($3,847)
$366
$7,455
$1,319
$5,293
$48
$42,059
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
149.2%
 
62.4%
(77.6%)
(267.5%)
1,106.5%
(24.0%)
515.0%
360.8%
 
(8.7%)
0.0%
(476.5%)
(195.3%)
 
(30.5%)
(96.1%)
419.2%
244.4%
(36.4%)
(95.0%)
165.8%
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
12/31/2008
$8,010
 
$1,379
$4,898
($1,366)
$2,039
($4,341)
($113)
$10,505
 
($3,976)
$0
$17
($3,960)
 
($2,948)
$9,446
$1,436
$383
$8,318
$959
$15,823
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
4.7%
 
(1.6%)
39.9%
79.8%
66.2%
(137.0%)
86.8%
143.4%
 
(61.2%)
0.0%
(29.2%)
(62.2%)
 
(251.4%)
483.8%
(70.0%)
0.0%
49.5%
149.7%
102.3%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2009
$84,197
$20,063
$64,134
 
$4,406
$18,248
$0
$693
$0
$40,788
 
$1,301
$42,088
$534
$41,554
$11,141
($10,455)
$19,958
 
 
$0
$0
$0
$0
$19,958
$0
$19,958
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
81.1%
101.9%
75.4%
 
59.2%
4.5%
0.0%
(7.6%)
0.0%
161.8%
 
347.1%
165.2%
(23.9%)
173.9%
277.1%
(148.6%)
149.2%
 
 
0.0%
0.0%
0.0%
0.0%
149.2%
0.0%
149.2%
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
12/31/2008
$46,497
$9,936
$36,561
 
$2,767
$17,463
$0
$750
$0
$15,581
 
$291
$15,871
$702
$15,170
$2,954
($4,205)
$8,010
 
 
$0
$0
$0
$0
$8,010
$0
$8,010
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
38.6%
52.8%
35.2%
 
186.7%
46.0%
0.0%
17.0%
0.0%
15.6%
 
52.4%
16.1%
46.9%
15.0%
49.6%
(18.0%)
4.7%
 
 
0.0%
0.0%
0.0%
0.0%
4.7%
0.0%
4.7%